Cancer Biomarker Market Size to Reach $39.7 Billion by 2028
The cancer biomarker market has witnessed substantial growth in recent years, and according to market analysis, it is poised to reach $22.77 billion in 2024 from $19.74 billion in 2023, reflecting a compound annual growth rate (CAGR) of 15.4%.
Astrong
This surge in market size is attributed to various factors, including the adoption of advanced technologies, strategic collaborations, and a focus on early detection through innovative biomarker research. The cancer biomarker market is projected to continue its rapid expansion, with an expected value of $39,772.47 million in 2028 at a rate of 15.04%. The market is then expected to grow at a CAGR of 15.89% from 2028 and reach $83,148.77 million in 2033. Key drivers of this cancer biomarker market growth include the shift towards patient-centric diagnostics, integration of biomarkers in clinical trials, emergence of multiplex biomarker panels, exploration of non-coding RNAs, and commercialization of biomarker tests. As the demand for precise and personalized cancer diagnostics continues to rise, companies in the cancer biomarker market are poised to drive innovation and shape the future of cancer care. The global cancer biomarker market is characterized by high concentration, with a few key players dominating the landscape. In 2022, the top ten competitors accounted for 51.6% of the total cancer biomarker market share. Leading the pack is Roche Diagnostics with a 15.9% share, followed by Novartis AG (9.9%), Illumina (5.3%), Hologic Inc. (4.9%), and Thermo Fisher Scientific (4.7%). Cancer biomarker companies are employing several strategies to maintain their competitive edge and drive growth. These strategies include: One of the notable advancements in cancer diagnostics is the utilization of artificial intelligence (AI) to analyze medical imaging data, including X-rays, MRIs, CT scans, and histopathology slides. AI algorithms can detect subtle patterns indicative of cancerous growths, enabling earlier and more accurate diagnoses. For instance, Ibex Medical Analytics introduced Galen Breast HER2, an AI-powered solution for precise HER2 scoring in breast cancer patients. This innovative technology aids pathologists in identifying invasive tumor areas and quantifying HER2 expression, facilitating targeted therapies and improving patient outcomes. For more information, be sure to read the report Cancer Biomarker Global Market Report 2024 by The Business Research Company. This report provides a thorough analysis of the cancer biomarker market, covering the period from 2018 to 2023 as the historical period, and from 2023 to 2028 as the forecast period. This report evaluates market dynamics across diverse regions and key economies within each region. An additional feature of the report is the inclusion of competitive benchmarking briefs, facilitating a financial comparison among leading players in the market. The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology. Find the company on LinkedIn, Twitter, Facebook, or YouTube for more.
The cancer biomarker market has witnessed substantial growth in recent years, and according to market analysis, it is poised to reach $22.77 billion in 2024 from $19.74 billion in 2023, reflecting a compound annual growth rate (CAGR) of 15.4%.Global Cancer Biomarkers Market Growth
Cancer Biomarker Market Share
Top Five Strategies in the Market
Artificial Intelligence in Cancer Diagnosis
Where to Learn More
About The Business Research Company
